Press Releases Chugai Pharmaceutical Co., Ltd.

Equities

4519

JP3519400000

Pharmaceuticals

Delayed Japan Exchange Other stock markets 03:30:00 14/05/2026 BST			5-day change	1st Jan Change
7,922.00 ^JPY	+1.50%		-2.14%	-3.89%

05-11	Jefferies Adjusts Chugai Pharmaceutical's Price Target to 8,500 Yen from 9,100 Yen, Keeps at Hold	MT
05-07	Japan's Nikkei blazes past 63,000 on earnings, Iran peace optimism; JGBs rally	RE

Press Releases

04-27	Chugai Pharmaceutical : Script (including Q&A)	PU
04-27	Chugai Pharmaceutical : Evaluation Results of Effectiveness of the Board of Directors (Apr. 27, 2026)	PU
04-24	Chugai Pharmaceutical : Supplementary Materials Supplementary Materials	PU
04-24	Chugai Pharmaceutical : Q1 Results (Jan-Mar 2026)	PU
04-09	Chugai Pharmaceutical : Announcement of Termination of Co-Promotion of Rituxan® in Japan (Anti-CD20 Monoclonal Antibody)	PU
03-27	Chugai Pharmaceutical : Voting Results (Extraordinary Report) of the 115th Annual General Meeting of Shareholders	PU
03-26	Chugai Pharmaceutical : Notice of Resolution of the 115th Annual General Meeting of Shareholders	PU
03-24	Chugai Pharmaceutical - Notice Regarding Discontinuation of Development of GYM329 in Spinal Muscular Atrophy and Facioscapulohumeral Muscular Dystrophy	AQ
03-23	Chugai Pharmaceutical : Obtains Regulatory Approval for Lunsumio and Polivy Combination Therapy for Additional Indication of Relapsed or Refractory Large B-cell Lymphoma	PU
03-22	Chugai Pharmaceutical : Notice Regarding Discontinuation of Development of GYM329 (Emugrobart) in Spinal Muscular Atrophy (SMA) and Facioscapulohumeral Muscular Dystrophy (FSHD)	PU
03-19	Chugai Pharmaceutical : Files for the Medical Device Component of the Port Delivery Platform with ranibizumab in Japan	PU
03-19	Chugai Pharmaceutical : Selected as a “Nadeshiko Brand” for FY2025	PU
03-11	Chugai Pharmaceutical Co., Ltd. - Roche's Announcement Regarding giredestrant	AQ
02-24	Chugai Pharmaceutical : Notice of Convocation of the 115th Annual General Meeting of Shareholders	PU
02-24	Chugai Pharmaceutical : Business Report of the 115th Annual General Meeting of Shareholders	PU
02-20	Chugai Pharmaceutical : Launches “ELEVIDYS” as Japan’s First Regenerative Medical Product for Duchenne Muscular Dystrophy	PU
02-19	Chugai Pharmaceutical : Anti-CD20 Monoclonal Antibody Rituxan® Approved for Treatment of Autoimmune Hemolytic Anemia	PU
02-09	Chugai Pharmaceutical : NXT007 Suggests Favorable Tolerability and Efficacy in Phase I/II Study for Hemophilia A Following Direct Switch from Emicizumab without Washout Period	PU
01-30	Chugai Announces 2025 Full Year Results and Forecasts for 2026	AQ
01-30	Chugai Relocates Head Office	AQ
01-30	Chugai Pharmaceutical Co., Ltd. - Revision of the Stock Compensation System	AQ
01-29	Chugai Pharmaceutical : Full Year Results (Jan-Dec 2025)	PU
01-29	Chugai Pharmaceutical : Supplementary Materials Supplementary Materials	PU
01-28	Chugai Pharmaceutical : Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer	PU
01-28	Chugai Pharmaceutical : Preclinical Results of the Anti-CTLA-4 Switch Antibody ROSE12 Published in the Journal for ImmunoTherapy of Cancer	PU